The latest update is out from Curvebeam AI Ltd. ( (AU:CVB) ).
CurveBeam AI Limited announced its interim financial results for the half-year ending December 31, 2024, reporting a 39% increase in revenue to $4.91 million compared to the previous year. The company also saw an 85% increase in purchase orders, indicating strong demand for its HiRise™ product. Despite a net loss of $10.52 million, CurveBeam AI managed to reduce operating losses and cash usage significantly, reflecting effective cash management strategies. The company aims to validate its enhanced HiRise™ for a major robotic-aided surgical system by Q3 FY25, which could significantly boost demand.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a fully integrated developer and manufacturer of point-of-care specialized medical imaging (CT) equipment, supported by a targeted range of AI-enabled SaaS-based clinical assessment solutions.
YTD Price Performance: -10.71%
Average Trading Volume: 294,598
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$48.72M
See more insights into CVB stock on TipRanks’ Stock Analysis page.